These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 21267012)

  • 21. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
    Anderson K; Jacobson JS; Heitjan DF; Zivin JG; Hershman D; Neugut AI; Grann VR
    Ann Intern Med; 2006 Mar; 144(6):397-406. PubMed ID: 16549852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.
    Gamble C; Havrilesky LJ; Myers ER; Chino JP; Hollenbeck S; Plichta JK; Kelly Marcom P; Shelley Hwang E; Kauff ND; Greenup RA
    Ann Surg Oncol; 2017 Oct; 24(11):3116-3123. PubMed ID: 28699130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing.
    Botkin JR; Smith KR; Croyle RT; Baty BJ; Wylie JE; Dutson D; Chan A; Hamann HA; Lerman C; McDonald J; Venne V; Ward JH; Lyon E
    Am J Med Genet A; 2003 Apr; 118A(3):201-9. PubMed ID: 12673648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of false-positive cancer screenings and cancer worry on risk-reducing surgery among BRCA1/2 carriers.
    Portnoy DB; Loud JT; Han PK; Mai PL; Greene MH
    Health Psychol; 2015 Jul; 34(7):709-17. PubMed ID: 25243716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers.
    Wu S; Weinstein SP; DeLeo MJ; Conant EF; Chen J; Domchek SM; Kontos D
    Breast Cancer Res; 2015 May; 17():67. PubMed ID: 25986460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer.
    Ladd MK; Peshkin BN; Senter L; Baldinger S; Isaacs C; Segal H; Philip S; Phillips C; Shane K; Martin A; Weinstein V; Pilarski R; Jeter J; Sweet K; Hatten B; Wurtmann EJ; Phippen S; Bro D; Schwartz MD
    Transl Behav Med; 2020 May; 10(2):337-346. PubMed ID: 30418620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.
    Fakkert IE; Jansen L; Meijer K; Kok T; Oosterwijk JC; Mourits MJ; de Bock GH
    Breast Cancer Res Treat; 2011 Aug; 129(1):157-64. PubMed ID: 21373873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea.
    Kim SI; Lim MC; Lee DO; Kong SY; Seo SS; Kang S; Lee ES; Park SY
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):333-40. PubMed ID: 26438354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breast MRI fibroglandular volume and parenchymal enhancement in BRCA1 and BRCA2 mutation carriers before and immediately after risk-reducing salpingo-oophorectomy.
    DeLeo MJ; Domchek SM; Kontos D; Conant E; Chen J; Weinstein S
    AJR Am J Roentgenol; 2015 Mar; 204(3):669-73. PubMed ID: 25714301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of hereditary breast and ovarian cancer.
    Yamauchi H; Takei J
    Int J Clin Oncol; 2018 Feb; 23(1):45-51. PubMed ID: 29185095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Attitudes toward Risk-Reducing Mastectomy and Risk-Reducing Salpingo-oophorectomy among Young, Unmarried, Healthy Women in Korea.
    Park B; Kim D; Kim J; Lee BY; Yoon J; Kim SW
    Cancer Res Treat; 2022 Apr; 54(2):375-382. PubMed ID: 34384016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study.
    Gornjec A; Merlo S; Novakovic S; Stegel V; Gazic B; Perhavec A; Blatnik A; Krajc M
    Radiol Oncol; 2020 May; 54(2):180-186. PubMed ID: 32463390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.
    Singh K; Lester J; Karlan B; Bresee C; Geva T; Gordon O
    Am J Obstet Gynecol; 2013 Apr; 208(4):329.e1-6. PubMed ID: 23333547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Very high uptake of risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers: A single-center experience.
    Harmsen MG; Arts-de Jong M; Horstik K; Manders P; Massuger LFAG; Hermens RPMG; Hoogerbrugge N; Woldringh GH; de Hullu JA
    Gynecol Oncol; 2016 Oct; 143(1):113-119. PubMed ID: 27430397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trends and timing of risk-reducing mastectomy uptake in unaffected BRCA1 and BRCA2 carriers in Slovenia.
    Ložar T; Žgajnar J; Perhavec A; Blatnik A; Novaković S; Krajc M
    Eur J Surg Oncol; 2021 Aug; 47(8):1900-1906. PubMed ID: 33812767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers.
    Fakkert IE; Mourits MJ; Jansen L; van der Kolk DM; Meijer K; Oosterwijk JC; van der Vegt B; Greuter MJ; de Bock GH
    Cancer Prev Res (Phila); 2012 Nov; 5(11):1291-7. PubMed ID: 23009828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRCA1/2 test results impact risk management attitudes, intentions, and uptake.
    O'Neill SC; Valdimarsdottir HB; Demarco TA; Peshkin BN; Graves KD; Brown K; Hurley KE; Isaacs C; Hecker S; Schwartz MD
    Breast Cancer Res Treat; 2010 Dec; 124(3):755-64. PubMed ID: 20383578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
    Arai M; Iwase T; Takazawa Y; Takeshima N
    Gan To Kagaku Ryoho; 2014 Nov; 41(11):1333-9. PubMed ID: 25434434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences among a Portuguese cohort of BRCA pathogenic/likely pathogenic variants carriers choosing risk-reducing mastectomy or intensive breast surveillance.
    Torres S; Peleteiro B; Magalhães A; Garrido L; Costa S; Fougo JL
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7529-7538. PubMed ID: 36971799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Online tool to guide decisions for BRCA1/2 mutation carriers.
    Kurian AW; Munoz DF; Rust P; Schackmann EA; Smith M; Clarke L; Mills MA; Plevritis SK
    J Clin Oncol; 2012 Feb; 30(5):497-506. PubMed ID: 22231042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.